Turning off cellular recycling helps researchers produce more drug proteins

With an unusual genetic modification which disabled cells' recycling systems, researchers found a way to make cells produce significantly larger amounts of the proteins used to discover and develop new medicines. The findings could help speed up drug development while reducing research and development costs.

Published in the journal, Cell Systems, the study addresses a persistent bottleneck in drug discovery: producing enough membrane proteins for research and development. Even though membrane proteins are the targets of around 60 percent of approved medicines, they're notoriously difficult to manufacture in useful quantities.

A team of researchers at KTH Royal Institute of Technology, in collaboration with AstraZeneca, reported significantly higher production of membrane proteins in a human cell line widely used in pharmaceutical research. They did so by disabling the pathway that cells normally rely on to recycle their own proteins. The result was increased production of three difficult-to-make target proteins - GIPR, GPR75 and P2X3 - by 30, 80 and 100 percent, respectively.

The researchers pursued the gene modification based on an unconventional hypothesis, says Johan Rockberg, professor of directed evolution at KTH. Rather than follow the well-worn path of trying to boost the production machinery in cells, the team instead disabled what Rockberg calls a cell's "clean-up crew" - or more specifically, the gene ULK1. ULK1 initiates autophagy, the process by which cells break down and recycle proteins and organelle. It's generally considered necessary for cell health, but the study shows removing the gene did no harm to the cells.

The modified cell line produced significantly more usable protein, including several membrane proteins."

Johan Rockberg, professor of directed evolution, KTH

"We expected cells without working autophagy to struggle," he says. "Instead, they produced more, and they did best with exactly the proteins that are usually hardest to obtain."

To understand how the cells coped with the removal of such a central part of their machinery, Alice Karlsson, doctoral student in biotechnology at KTH, took a deep dive into activity within the cells.

"The most rewarding part was seeing the effect of knocking out ULK1 and that it led to clear signs in the transcriptome with downregulation of autophagy and downstream processes," Karlsson says.

"The biggest surprise was that it also translated into higher yields of our model proteins," she says.

The finding points to autophagy as a target for host cell engineering more broadly, alongside the established approaches of strengthening the secretory machinery.

Beyond manufacturing, the observed effects on cellular metabolism and protein turnover may also be of interest where those processes play a central role, such as in neurodegenerative conditions marked by protein aggregation and impaired clearance.

The study is a collaboration between KTH and AstraZeneca, with PhD student Alice Karlsson (KTH) as first author. Melanie Dannemeyer (AZ) and Robert G. Roth (AZ) and Johan Rockberg (KTH) are corresponding authors. The work was funded by the Knut and Alice Wallenberg Foundation, AstraZeneca and the Swedish innovation agency Vinnova through GeneNova, AAVNova, CellNova and AdBIOPRO.

Source:
Journal reference:

Karlsson, A., et al. (2026). ULK1 knockout increases recombinant transcript abundance and improves recombinant membrane protein expression. Cell Systems. DOI: 10.1016/j.cels.2026.101779. https://www.cell.com/cell-systems/fulltext/S2405-4712(26)00261-9

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
DNA modification linked to milder muscular dystrophy disease outcomes